李氏大药厂2024年年报

2024ANNUAL REPORT CONTENTS Corporate Information2Corporate Profile4Financial Highlights7Five-Year Financial Summary9Chairman’s Statement10Management Discussion and Analysis13Directors and Key Personnel Profiles24Report of the Directors32Corporate Governance Report55Independent Auditor’s Report66Consolidated Statement of Profit or Loss75Consolidated Statement of Profit or Loss andOther Comprehensive Income76Consolidated Statement of Financial Position77Consolidated Statement of Changes in Equity79Consolidated Statement of Cash Flows81Notes to the Consolidated Financial Statements83Definition230 Corporate Information BOARD OF DIRECTORS Executive Directors Ms. Lee Siu Fong(Chairman)Ms. Leelalertsuphakun Wanee(Managing Director) Non-executive Directors James Charles Gale Dr. Li XiaoyiMr. James Charles GaleMr. Huang Zuie-Chin(appointed with effect from 2 July 2024) Independent Non-executive Directors Dr. Chan Yau Ching, BobMs. Cheang Yee Wah, EvaDr. Tsim Wah Keung, Karl COMPANY SECRETARY Mr. Chow Yiu Ming AUDIT COMMITTEE Dr. Chan Yau Ching, Bob(Chairman)Ms. Cheang Yee Wah, EvaDr. Tsim Wah Keung, Karl REMUNERATION COMMITTEE Dr. Tsim Wah Keung, Karl(Chairman)Ms. Leelalertsuphakun WaneeDr. Chan Yau Ching, Bob NOMINATION COMMITTEE Ms. Lee Siu Fong(Chairman)Dr. Chan Yau Ching, BobDr. Tsim Wah Keung, Karl MANAGEMENT COMMITTEE Ms. Leelalertsuphakun Wanee(Chairman)Ms. Lee Siu Fong AUDITOR Confucius International CPA LimitedCertified Public Accountants LEGAL ADVISERS King & Wood Mallesons(Hong Kong law)Beijing Docvit Law Firm(PRC law) REGISTERED OFFICE PO Box 309Ugland House, Grand CaymanKY1-1104, Cayman Islands PO Box 309Ugland House, Grand CaymanKY1-1104, Cayman Islands PLACE OF BUSINESS IN HONG KONG 1/F, Building 20E, Phase 3Hong Kong Science Park, ShatinHong Kong 20E HONG KONG SHARE REGISTRAR ANDTRANSFER OFFICE 183171712–1716 Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th Floor, Hopewell Centre183 Queen’s Road East, WanchaiHong Kong AUTHORISED REPRESENTATIVES Ms. Lee Siu FongMs. Leelalertsuphakun Wanee WEBSITE www.leespharm.com www.leespharm.com STOCK CODE 950 950 Corporate Profile The Company is a research-driven and market-oriented biopharmaceuticalcompany with 30 years’ experience in the pharmaceutical industry inChina. With solid infrastructures in drug development, clinical development,regulatory,manufacturing,sales and marketing,the Group hasestablished extensive partnerships with around 30 international companiesand currently markets over 25 proprietary, generic and licensed-inpharmaceutical products in Mainland China, Hong Kong, Macau andTaiwan. The Group focuses on several key therapeutic areas such as cardiovascularhealth, woman’s health, paediatrics, rare diseases, oncology, dermatology,and obstetrics. It maintains a strong and carefully curated projectpipeline under different development stages stemming from both internalresearch and development as well as from the licensing of development,commercialisation, and manufacturing rights from various United States,European and Japanese companies. The Group carries out its sales and distribution activities in Hong Kong,Macau, Taiwan and Mainland China through Hong Kong and Taiwan officesand branch offices in Chongqing, Guangzhou, Shanghai and Beijing withdirect and channel sales network covering most of the provinces andcities in Mainland China, marketing both domestic self-developed andgeneric products and overseas licensed-in products. Zhaoke Hefei iscurrently operating the manufacturing plant of the Group located in Hefei,Anhui Province of the PRC, comprising four GMP-compliant workshopsfor the production of topical gel, lyophilised powder for injection, smallvolume parenteral solutions and eye gel. Zhaoke Guangzhou is currentlyoperating the manufacturing site in Nansha District, Guangzhou of the PRCwhich include a complete range of solid dosage production lines for thedevelopment and manufacturing of tablets and capsules. GMP The mission of the Group is to become a successful biopharmaceuticalgroup in Asia providing innovative products to fight diseases and improvehealth and quality of life. Financial Highlights Financial Highlights PROFIT ATTRIBUTABLE TO THEOWNERS OF THE COMPANY(HK$’000) REVENUE (HK$’000) EQUITY ATTRIBUTABLE TO THEOWNERS OF THE COMPANY(HK$’000) BASIC EARNINGS PER SHARE(HK CENTS) Five-Year Financial Summary Chairman’s Statement Dear Shareholders, I am delighted to present the annual report for 2024 on behalf of theCompany and the Board. In 2024, the Chinese pharmaceutical industry was marked by rapidgrowth and significant innovation. This progress was driven by anaging population with increasing medical needs and strong governmentsupport for healthcare innovations. While the market grows, propelledby breakthroughs in biologics and AI-driven drug discovery, it also faceschallenges such as pricing reforms, VBP policies, and global geopoliticalissues like trade